Introduction
============

Breast cancer (BC) is the most frequent malignancy among women worldwide, with an estimated 14 million new cases and 8 million mortalities in 2012, which is projected to rise by at least 70% by 2030 ([@b1-ol-0-0-5360]). It is most common in women aged \>50 years (\>75% of all cases), in contrast to those aged ≤40 years, who represent only 5--25% of all BC cases. Notably, BC in these younger women is generally considered to bear a more unfavorable disease outcome, with a substantially shorter overall survival as compared with older women ([@b2-ol-0-0-5360],[@b3-ol-0-0-5360]).

Indeed, several multivariate analyses have shown that young age is an independent predictor of unfavorable disease outcome ([@b4-ol-0-0-5360]), and it has been suggested to be associated with a more aggressive tumor biology that potentially reduces the survival expectancy ([@b5-ol-0-0-5360],[@b6-ol-0-0-5360]). This increased aggressiveness of BC among younger women has been attributed to mutations in the BC susceptibility proteins, breast cancer (BRCA)1 and 2 ([@b5-ol-0-0-5360],[@b6-ol-0-0-5360]). In addition, BC in younger women is often diagnosed at more advanced stages than in older women. In addition, BC tumors in younger women are: i) More frequently negative for estrogen receptor (ER); ii) show extensive lymphovascular invasion (LVI); iii) exhibit increased cell proliferation (assessed by the Ki-67 marker); and v) demonstrate overexpression of p53 oncogene ([@b6-ol-0-0-5360]).

Molecular profiling has suggested that race and ethnicity may be other important factors associated with the development of BC, particularly with its poor prognosis among younger women, with those of African American origin being at the highest risk of increased mortality ([@b7-ol-0-0-5360]). All of the aforementioned evidence indicates that BC in younger women bears a worse disease outcome compared with older women. This difference is only partially explained by the fact that mammography screening and clinical breast examinations are targeted to women aged \>40 years ([@b8-ol-0-0-5360]).

In Brazil, the incidence and mortality rates of BC are relatively high ([@b9-ol-0-0-5360],[@b10-ol-0-0-5360]). Compared with North America, where the incidence of BC among younger women has plateaued ([@b11-ol-0-0-5360]), Brazil continues to present with relatively high incidence rates among women aged 30--39 years ([@b12-ol-0-0-5360]). Considering the increased BC mortality among young women of African origin ([@b7-ol-0-0-5360]), it is of note that Brazil is a country with a relatively high population of African descent, increasing the importance of assessing the characteristics of BC among young women in this country.

To the best of our knowledge, the present study analyzed the largest cohort of patients with BC aged ≤40 years (n=376) at a single institution to date, by comparing an extensive set of clinicopathological characteristics and other variables with a similarly sized cohort of BC patients aged 50--69 years (n=362). The aim of the present study was to determine whether disease outcome in younger women is poorer than that in the older women and, if supported, to estimate the significant determinants of this differential outcome in multivariate models.

Patients and methods
====================

### Study design

The present retrospective analytical study was based on the hospital records of women with invasive BC (ICD-10: C50) who were admitted to Barretos Cancer Hospital, Pio XII Foundation (Barretos, Brazil) with no previous treatment between January 1985 and December 2002. During this 17-year period, a total of 4,134 women were examined. Of those, 1,735 women were eligible and initially selected into the present study, according to the inclusion and exclusion criteria. The patients were divided into two groups: A younger group (≤40 years of age) and an older group (50--69 years of age). The original cohort included 469 patients aged ≤40 years and 1,266 patients aged 50--69 years. From this original cohort, 400 women were selected from each group using a random sample generator (SPSS software, version 20.0.0.1; IBM SPSS, Armonk, NY, USA). Clinical treatment and follow-up data were obtained from the patients\' medical records. Patients without follow-up information for \>12 months were contacted by telephone to update this information.

### Inclusion and exclusion criteria

Patients that had undergone cancer treatment prior to admission (1,290 patients), those aged 41--49 years of age (666 patients) and those aged ≥70 years (443 patients) were excluded from the cohort. Finally, 24 women were excluded from the ≤40 years age group and 38 women were excluded from the 50--69 years age group due to a lack of clinical or treatment information, or due to a non-invasive disease.

### Sample size estimation

To calculate the sample size, the following assumptions were made: 30--40% mortality ([@b13-ol-0-0-5360],[@b14-ol-0-0-5360]), ±7.5% estimation error, 5% type I error and 90% power. These conditions indicated that between 360 and 400 patients in both groups would be required for an adequately powered study. Accordingly, the final analysis included 376 women aged ≤40 years and 362 women aged 50--69 years.

### Definitions of BC characteristics

BC was defined as multi-centric or multi-focal disease. Multi-centric was defined as a disease present in \>1 quadrant of the breast, whereas multi-focal disease was defined as a second tumor located at a distance of at least 5 cm from the primary tumor. The tumors were also classified as synchronous or metachronous. The criteria recommended by the National Cancer Institute were used to assess comorbidities ([@b15-ol-0-0-5360]).

Immunohistochemistry (IHC) was routinely performed using paraffin sections of the tumors to classify their patterns of ER, progesterone receptor (PR) and C-erB-2 oncoprotein expression. Tumors that were negative for all of these markers were considered 'triple negative' for IHC expression. Assessment of positive reactions was performed according to the guidelines in common use for ER and PR, and the scoring system proposed by Allred *et al* was used to determine the proportion of stained nuclei and the staining intensity ([@b16-ol-0-0-5360]).

Tumor staging was based on the criteria proposed by the International Union Against Cancer and the American Joint Committee on Cancer ([@b17-ol-0-0-5360]), and the TNM staging system was used to evaluate the BC in three aspects: Tumor size and extension (T), regional lymph node involvement (N), and the presence of distant metastasis (M). Following the determination of the T, N and M classifications, stage 0, I, II, III or IV was assigned.

### Statistical analysis

Statistical analyses were run using SPSS software for Windows (version 20.0.0.1; IBM SPSS). Frequency tables used for univariate analysis of overall survival (OS; the time from diagnosis until mortality or date last seen alive) were based on the Kaplan-Meier method, where stratum-specific outcomes were compared using log-rank (Mantel-Cox) statistics. To adjust for covariates, a Cox proportional hazards regression model was used, and covariates (as listed separately) were entered in a stepwise backwards manner using the default values of entry (P=0.05) and removal (P=0.10). The variables that were significant in the univariate analysis were included in the multivariate model. All of the statistical tests were two-sided and P\<0.05 indicated a statistically significant difference.

### Ethics

The present study was approved by the Research Ethics Committee of Barretos Cancer Hospital, Pio XII Foundation.

Results
=======

The demographic characteristics of the patients in the two series are presented in [Table I](#tI-ol-0-0-5360){ref-type="table"}. The main clinical features are shown in [Table II](#tII-ol-0-0-5360){ref-type="table"}. The histopathological features and treatment characteristics are shown in [Tables III](#tIII-ol-0-0-5360){ref-type="table"} and [IV](#tIV-ol-0-0-5360){ref-type="table"}, respectively.

The two groups displayed significant differences in various characteristics. The older group showed a higher proportion of women with low educational level (up to 8 years of school) as compared with the younger group (77.1 vs. 55.9%, respectively; P\<0.001) ([Table I](#tI-ol-0-0-5360){ref-type="table"}).

[Table II](#tII-ol-0-0-5360){ref-type="table"} shows that the groups had no differences in the presence of nodules or multicentric cancer at the first examination. The younger group had a higher proportion of multi-focal cancer and bilateral cancer as compared with the older group (6.1 vs. 2.5%, P=0.017 and 9.8 vs. 5.8%, P=0.037, respectively). Comorbidity was less frequent in the younger group than in the older group; one or two comorbidities were found in 30.3 vs. 48.3% of patients (P\<0.001), respectively ([Table II](#tII-ol-0-0-5360){ref-type="table"}).

As indicated in [Table III](#tIII-ol-0-0-5360){ref-type="table"}, no significant differences were identified between the groups in terms of histological types of the cancer or disease staging. The tumors in the younger group showed a greater frequency of a low degree of differentiation (23.1 vs. 16.6%; P=0.035), reduced blood vessel invasion (1.1 vs. 1.9%; P=0.003), reduced LVI (21.3 vs. 22.4%; P\<0.001) and reduced perineural invasion (4.8 vs. 3.6%; P=0.055) as compared with the lesions in the older group ([Table III](#tIII-ol-0-0-5360){ref-type="table"}).

The proportion of tumors that were positive for ER expression was significantly lower in the younger group than in the older group (33.5 vs. 42.8%; P=0.014). The two groups had similar negative rates of PR and C-erB-2 expression ([Table III](#tIII-ol-0-0-5360){ref-type="table"}). Tumors classified as triple negative were more frequent among the younger women (10.1 vs. 6.4%; P=0.027) ([Table III](#tIII-ol-0-0-5360){ref-type="table"}).

The two groups were similar in terms of the number of dissected lymph nodes. Although the younger group underwent radical mastectomy less frequently than the older group, the difference was not statistically significant (59.6 vs. 64.6%, respectively; P=0.078) ([Table III](#tIII-ol-0-0-5360){ref-type="table"}). There was a higher proportion of breast reconstruction in the younger group as compared with the older group (20.7 vs. 3.9%; P\<0.001) ([Table IV](#tIV-ol-0-0-5360){ref-type="table"}). Furthermore, the groups had undergone similar neo-adjuvant treatments [Table IV](#tIV-ol-0-0-5360){ref-type="table"}); adjuvant hormone therapy was used less frequently in the younger than in the older group, but this difference was only of borderline significance (27.7 vs. 36.2%; P=0.056) ([Table IV](#tIV-ol-0-0-5360){ref-type="table"}).

The duration of follow-up ranged between 0 and 22.6 years, with a mean of 6.1 years and 8.5 months when mortality was excluded. The follow-up data were similar in the two groups (P=0.816). After 5 and 10 years, 4.9 and 10.5% of the patients, respectively, were lost to follow-up (data not shown). The OS rates were not significantly different between the groups (P=0.421) ([Fig. 1](#f1-ol-0-0-5360){ref-type="fig"}).

Univariate analysis showed that the following characteristics were significantly associated with prognosis in the younger group: Second cancer (P=0.004), bilateral BC (P=0.100), familial history (P=0.086), menopause at diagnosis (P=0.026), associated diseases (P=0.077), tumor size (mastectomy) (P=0.075), T, N and M stage (P\<0.001), degree of differentiation (P=0.127), perineural invasion (P=0.056), LVI (P=0.004), lymph node invasion (P\<0.001), ER status (P=0.002), PR status (P=0.043), type of breast surgery (P\<0.001), axillary surgery (P\<0.001), number of lymph nodes dissected (P\<0.001), breast reconstruction (P\<0.001), neoadjuvant chemotherapy (P\<0.028), chemotherapy (P\<0.001) and hormone therapy (P\<0.001) ([Tables V](#tV-ol-0-0-5360){ref-type="table"}--[VIII](#tVIII-ol-0-0-5360){ref-type="table"}).

In the older group, the following variables were significantly associated with prognosis: Period of treatment (P=0.002), ethnicity (P=0.129), marital status (P=0.170), palpable nodules (P=0.062), tumor size (mastectomy) (P=0.042), T, N and M stage (P\<0.001), degree of differentiation (P\<0.001), peri-neural invasion (P=0.095), blood vessel invasion(P\<0.001), LVI (P=0.003), lymph node invasion (P\<0.001), ER status (P=0.001), PR status (P=0.015), C-erB-2 expression (P=0.006), type of breast surgery (P\<0.001), axillary surgery (P\<0.001), number of lymph nodes dissected (P=0.005), neo-adjuvant chemotherapy (P=0.010), chemotherapy (P\<0.001), hormone therapy (P\<0.001), and radiotherapy (P=0.016). None of the other variables were statistically significant predictors of survival ([Tables V](#tV-ol-0-0-5360){ref-type="table"}--[VIII](#tVIII-ol-0-0-5360){ref-type="table"}).

When stratified by clinical stage, no significant differences in the stage-specific survival rates between the two age groups were found (P=0.421) ([Fig. 1](#f1-ol-0-0-5360){ref-type="fig"}). However, when the groups were stratified by the period of treatment, significant differences in survival rates were observed between the two groups during the treatment period between 1997 and 2002 (young vs. old group, 40.7 vs. 60.0% survival, P=0.028) ([Fig. 2](#f2-ol-0-0-5360){ref-type="fig"}).

In the multivariate analysis, second cancer \[hazard ratio (HR), 2.20; 95% confidence interval (CI), 1.500--29.044; P=0.013\] and bilateral BC (HR, 6.60; 95% CI, 1.228--3.930; P=0.008) were independent predictors of a poor outcome, with an increased risk of mortality in the younger group. C-erB-2 (HR, 1.97; 95%; CI, 1.003--3.869; P=0.049) was a positive predictor of a poor outcome in the older group, showing an increased risk of mortality. The ER status and TNM stage were significantly associated with disease prognosis in both groups ([Tables IX](#tIX-ol-0-0-5360){ref-type="table"} and [X](#tX-ol-0-0-5360){ref-type="table"}).

Discussion
==========

The results described herein reveal important differences between the younger and older patients with BC. This is an almost unanimously accepted fact among BC investigators. Notably, however, the present study was unable to confirm the most controversial of these issues, the suggested worse survival rate of young patients with BC, and failed to identify any difference in disease outcome between the two study groups. This finding is of major importance, asthe OS (Kaplan-Meier) did not reveal significant differences between the two groups, despite several parameters indicating that a more aggressive tumor biology is confined to the younger patients. Only when calculated for the treatment period 1997--2002 were the OS rates significantly worse among young women. We propose that there are several explanations for this finding, with insights discussed herein.

Whether there are clinicopathological differences in BC between younger and older women remains a controversial issue. Typically, the young BC age group ranges from 35 ([@b13-ol-0-0-5360],[@b18-ol-0-0-5360],[@b19-ol-0-0-5360]) to 40 ([@b2-ol-0-0-5360],[@b14-ol-0-0-5360],[@b20-ol-0-0-5360],[@b21-ol-0-0-5360]), however, there is no clear consensus supporting these strict age limits for young and old. However, BC is more frequent in women aged \>50 years old. In a population-derived cohort from Brazil, the prevalence of BC was found to be 14% ([@b12-ol-0-0-5360]), 4.5% of these patients were aged ≤35 years ([@b3-ol-0-0-5360]) and 26.4% were aged ≤40 years ([@b2-ol-0-0-5360]).

Thus, in the present study, a 40-year cut-off was used to stratify the women as younger or older. This criterion was partially supported by epidemiological data demonstrating different tumor biology in different age groups ([@b14-ol-0-0-5360],[@b22-ol-0-0-5360]). It is also important to emphasize that in Europe, regular mammography screening is a standard practice for women aged 50--69 years. This group is considered to be a biologically distinct group at high risk of developing BC with particular radiological characteristics ([@b23-ol-0-0-5360]). For this reason, women aged 50--69 years old were selected for comparison in the present study. As BC studies have different definitions regarding age groups, it is challenging to provide a reasonable comparison between different studies.

A number of reports also disagree regarding the importance of including different types of BC, for example, carcinoma *in situ* (CIS) ([@b13-ol-0-0-5360],[@b21-ol-0-0-5360]) or metastatic disease ([@b2-ol-0-0-5360],[@b24-ol-0-0-5360]). Other studies disagree regarding the pertinence of including patients with clinical stage I and II ([@b25-ol-0-0-5360],[@b26-ol-0-0-5360]) or clinical stages I--III ([@b2-ol-0-0-5360],[@b20-ol-0-0-5360],[@b24-ol-0-0-5360]) cancer. The present study included TNM stage, and excluded cases of CIS due to their different histological features ([@b27-ol-0-0-5360]) and relatively favorable disease outcome.

The present study is based on robust parameters that were selected to reflect the true significance of the behavior of BC in young women. To the best of our knowledge, the current study includes the largest cohort of patients with BC aged ≤40 years (n=376) reported from a single institution to date. Worldwide, few institutions have studied larger samples ([@b24-ol-0-0-5360],[@b28-ol-0-0-5360]) and the majority of large studies have been based on cancer registries ([@b7-ol-0-0-5360],[@b14-ol-0-0-5360],[@b21-ol-0-0-5360]).

The present study included a large number of patients with invasive BC presenting at advanced clinical stages. These features are not unusual and are inherent to the existing healthcare system in Brazil. Brazilian women have limited access to clinics that provide mammography examinations and organized population-based screening programs do not exist; consequently, the majority of the BC cases in Brazil are detected at advanced stages. This is in contrast to the situation in developed countries, where regular mammography screening enables the detection of the majority of cases of BC at an early stage ([@b14-ol-0-0-5360],[@b19-ol-0-0-5360],[@b21-ol-0-0-5360]). Indeed, prior to 2002, there was no formal recommendation from the Brazilian Health Authorities to provide mammography examinations in asymptomatic women. Therefore, as the presence of palpable and/or ulcerated lesions were a requirement for medical care, a substantial proportion of women exhibited these signs at their first examination. These characteristics are an inherent bias of the present study design resulting in a cohort enriched by BC patients with aggressive tumors at baseline. However, the overall relative survival rate of the older women (50--69 years old) improved between 1997 and 2002, attributable to improvements in treatment, such as chemotherapy and hormone therapy ([@b29-ol-0-0-5360]).

Mammography is undoubtedly an important diagnostic tool for non-palpable lesions, despite sensitivity limitations among women aged ≤40 years. It is speculated that regular programs for BC prevention could minimize the number of cases of advanced stage disease in Brazil ([@b30-ol-0-0-5360]). Hereditary BC associated with BRCA1/2 mutations have a prevalence of \~2.3% ([@b31-ol-0-0-5360]) in Brazil. Furthermore, studies of Latin American women have demonstrated that a family history of BC is less prevalent in Latin America than in the North American population ([@b32-ol-0-0-5360]). In the present study, mutations were not investigated, however, the familial history of BC was similar between the two study groups. However, the presence of second cancer was similar in the younger and older groups; this is consistent with the results of a previous study, where it was attributed to longer exposures to pathogenic factors ([@b33-ol-0-0-5360]).

The prevalence of bilateral disease was higher in the younger age group and is one of the indicators of more aggressive tumors, for example tumors with T stage II/III, grade III differentiation, negative ER/PR status and positive lymph node invasion are more aggressive ([@b33-ol-0-0-5360]). Conversely, the older women more frequently presented with other diseases associated with their BC, which can have an adverse influence on clinical outcome and contribute to a poor prognosis ([@b34-ol-0-0-5360]). However, the present results identified indicators of worse prognosis to be more common among the younger women.

Accordingly, younger women presented with a higher proportion of tumors with grade III differentiation (poorly differentiated), as reported in a previous study ([@b33-ol-0-0-5360]). Similarly, the present study observed significant differences between the two groups in terms of perivascular blood vessel invasion and LVI, with older women showing higher proportions of both types of invasion. Notably, this result conflicts with the previously reported data ([@b35-ol-0-0-5360],[@b36-ol-0-0-5360]).

The present study also observed that a higher proportion of older women were positive for ER compared with younger women. This finding is consistent with the results of a previous study, in which advanced age was correlated with positive ER status and vice versa ([@b36-ol-0-0-5360]). This observation also agrees with the disease outcome data of the current cohort, as a negative ER status is typically associated with a more unfavorable prognosis. By contrast, PR expression did not significantly differ between the two age groups, in agreement with a previous report ([@b26-ol-0-0-5360]). Conversely, a previous study observed that a negative PR status occurs more frequently in the BC of younger women ([@b35-ol-0-0-5360]). However, the prognostic value of PR was visible only as a part of an algorithm, but not on its own ([@b37-ol-0-0-5360]). The present findings also revealed that triple negative BC, which are considered to predict a poor prognosis, were more common in younger women, as previously reported ([@b13-ol-0-0-5360]).

As anticipated, more important differences in factors that usually influence the efficacy of treatment were observed between the two groups, including tumor stage at the time of diagnosis, tumor characteristics and comorbidities. Of note, the present study included patients with follow-up times of up to 22 years (mean, 6.75 years). This is another important feature of the present study, as only a small number of studies have reported long-term follow-up data of 10 ([@b20-ol-0-0-5360],[@b25-ol-0-0-5360],[@b36-ol-0-0-5360],[@b38-ol-0-0-5360]) or 15 years ([@b2-ol-0-0-5360],[@b14-ol-0-0-5360],[@b24-ol-0-0-5360],[@b28-ol-0-0-5360]). In addition, BC treatment strategies have undergone rapid developments in the past two decades, and this development may have contributed to the prognostic differences between the two groups included in the current study. In the younger group, fewer patients received adjuvant hormone therapy and more women received palliative chemotherapy when compared with the older group. This is a clear limitation inherent to all retrospective studies where active intervention is no longer possible. However, the current observations clearly support proposals to also initiate monitoring programs for long-term BC patients.

Finally, the present results did not show significant differences in survival rates between the two study groups ([Fig. 1](#f1-ol-0-0-5360){ref-type="fig"}). By contrast, a previous study conducted in central Brazil demonstrated a significant difference in survival rates between patients aged ≤40 years and those aged 40--50 years (P=0.0002) or those aged \>50 years (P=0.03). However, this study excluded clinical stage IV disease and included far fewer patients than the present study ([@b20-ol-0-0-5360]). A previous study reported that BC mortality remains high among young patients, with an OS of \~60% over 5 years, compared with 85% among women aged \>50 years ([@b20-ol-0-0-5360]). The equal survival rates between young and old women observed in the present study have been reported in previous studies ([@b38-ol-0-0-5360],[@b39-ol-0-0-5360]), however, in general, the results have been highly variable among the published literature ([@b40-ol-0-0-5360]--[@b43-ol-0-0-5360]).

In conclusion, BC among young women is generally considered to be more aggressive and associated with a worse prognosis compared with BC in older women, whereas the prognostic value of age itself remains more controversial. The results of the present study suggest that BC in young women is associated with numerous pathological features of aggressiveness, including tumor grade, hormone receptor status and degree of differentiation, having been implicated as independent determinants of BC prognosis. However, the OS rates of the two age groups proved to be very similar, except when the data were stratified by the treatment period. For women treated during 1997--2002, the 10-year survival rate of the older women was \~60% compared with 40.7% in the younger cohort. The current study concludes that this increase in 10-year survival is due largely to improvements in treatment, increased early diagnosis and certain tumor characteristics, with the patient\'s age itself not being an independent prognostic factor. The present study indicates that medical advances associated with prevention of breast cancer may improve screening programs, which may therefore increase early diagnosis and subsequently lower mortality rates.
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###### 

Demographics of patients with breast cancer stratified by age group.

                        ≤40 years (n=376)   50-69 years (n=362)                   
  --------------------- ------------------- --------------------- ------- ------- ---------
  Period of treatment                                                             
    1985--1990            59                15.7                    65    18.0    0.078
    1991--1996          108                 28.7                    78    21.5    
    1997--2002          208                 55.3                  217     59.9    
    N/A                     1                 0.3                     2     0.6   
  Schooling, years                                                                
    0--8                210                 55.9                  279     77.1    \<0.001
    9--11               106                 28.2                    32      8.8   
    ≥12                   57                15.2                    34      9.4   
    N/A                     3                 0.8                   17      4.7   
  Overweight                                                                      
    No                  284                 75.5                  219     60.5    \<0.001
    Yes                   44                11.7                    90    24.9    
    N/A                   48                12.8                    53    14.6    
  Ethnicity                                                                       
    White               297                 79.0                  288     79.6    0.360
    Non-white             76                20.2                    70    19.3    
    N/A                     3                 0.8                     4     1.1   
  Marital status                                                                  
    Married             254                 67.6                  214     59.1    \<0.001
    Single/divorced     110                 29.3                  134     37.0    
    N/A                   12                  3.2                   14      3.9   

N/A, not available.

###### 

Main clinical features of patients with breast cancer stratified by age group.

                            ≤40 years (n=376)   50-69 years (n=362)                   
  ------------------------- ------------------- --------------------- ------- ------- ---------
  Palpable nodules                                                                    
    No                        19                  5.1                   20      5.5   0.761
    Yes                     356                 94.7                  338     93.4    
    N/A                         1                 0.3                     4     1.1   
  Multicentric cancer                                                                 
    No                      358                 95.2                  344     95.0    0.158
    Yes                       11                  2.9                     5     1.4   
    N/A                         7                 1.9                   12      3.3   
  Multifocal cancer                                                                   0.017
    No                      346                 92.9                  341     94.2    
    Yes                       23                  6.1                     9     2.5   
    N/A                         1                 0.3                   12      3.3   
  Second cancer                                                                       
    No                      371                 98.7                  352     97.2    0.327
    Yes                         4                 1.1                     7     1.9   
    N/A                         8                 2.1                     3     0.8   
  Bilateral breast cancer                                                             0.037
    No                      331                 88.0                  336     92.8    
    Yes                       37                  9.8                   21      5.8   
    N/A                         8                 2.1                     5     1.4   
  Familial history                                                                    
    No                      211                 56.1                  181     50.0    0.611
    Yes                       49                13.0                    36      9.9   
    Other malignancies        74                19.7                    53    14.6    
    N/A                       42                11.2                    92    25.4    
  Menopause at diagnosis                                                              
    No                      363                 96.5                    38    10.5    \<0.001
    Yes                         7                 1.9                 226     62.4    
    N/A                         6                 1.6                   98    27.1    
  Comorbidities                                                                       \<0.001
    Absent                  256                 68.1                  145     40.1    
    1 or 2 diseases         114                 30.8                  175     48.3    
    N/A                         6                 1.6                   42    11.6    

N/A, not available.

###### 

Histological features of patients with breast cancer stratified by age group.

                                                   ≤40 years (n=376)   50--69 years (n=362)                   
  ------------------------------------------------ ------------------- ---------------------- ------- ------- ---------
  Histological diagnosis                                                                                      
    Ductal carcinoma                               301                 80.1                   289     79.8    0.867
    Lobular carcinoma                                59                15.7                     54    14.9    
    Miscellaneous                                    15                  4.0                    17      4.7   
    N/A                                                1                 0.3                      2     0.6   
  Tumor size (mastectomy), cm                                                                                 
    ≤2                                               54                14.4                     74    20.4    0.185
    \>2                                            187                 49.7                   195     53.9    
    N/A                                            135                 35.9                     93    25.7    
  T^[a](#tfn3-ol-0-0-5360){ref-type="table-fn"}^                                                              
    TI/TII                                         196                 52.1                   210     58.0    0.354
    TIII/TIV                                         84                22.3                   106     29.3    
    N/A                                              94                25.0                     46    12.7    
  N^[a](#tfn3-ol-0-0-5360){ref-type="table-fn"}^                                                              
    Positive                                       147                 39.1                   156     43.1    0.183
    Negative                                       197                 52.4                   170     47.0    
    N/A                                              32                  8.5                    36      9.9   
  M^[a](#tfn3-ol-0-0-5360){ref-type="table-fn"}^                                                              
    No                                             311                 82.7                   311     85.9    0.740
    Yes                                              38                10.1                     35      9.7   
    N/A                                              27                  7.2                    16      4.4   
  Differentiation degree                                                                                      
    I/II                                           190                 50.5                   201     55.5    0.035
    III                                              87                23.1                     60    16.6    
    N/A                                              99                26.3                   101     27.9    
  Perineural invasion                                                                                         
    No                                             241                 64.1                     84    23.2    
    Yes                                              18                  4.8                    13      3.6   0.055
    N/A                                            117                 31.1                   276     76.8    
  Blood vessel invasion                                                                                       
    No                                             248                 66.0                     79    21.8    
    Yes                                                4                 1.1                      7     1.9   0.007
    N/A                                            124                 33.0                   276     76.2    
  Lymphovascular invasion                                                                                     
    No                                             189                 50.3                     53    14.6    \<0.001
    Yes                                              80                21.3                     81    22.4    
    N/A                                            107                 28.5                   228     63.0    
  Lymph node invasion                                                                                         
    N1 ([@b1-ol-0-0-5360]--[@b3-ol-0-0-5360])        78                20.7                     67    18.5    0.535
    N2 ([@b4-ol-0-0-5360]--[@b9-ol-0-0-5360])        55                14.6                     49    13.5    
    N3 (≥10)                                         42                11.2                     35      9.7   
    N/A                                            201                 53.5                   211     58.3    
  Estrogen receptor                                                                                           
    Negative                                         89                23.7                     67    18.5    0.014
    Positive                                       126                 33.5                   155     42.8    
    N/A                                            161                 42.8                   140     38.7    
  Progesterone receptor                                                                                       
    Negative                                         90                23.9                     85    23.5    0.468
    Positive                                       124                 33.0                   135     37.3    
    N/A                                            162                 43.1                   142     39.2    
  C-erB-2 oncoprotein                                                                                         
    Negative                                       117                 31.3                   125     34.5    0.032
    Positive                                         58                15.4                     53    14.6    
    N/A                                            201                 53.5                   184     50.8    
  Triple negative                                                                                             
    No                                             136                 36.2                   155     42.8    0.027
    Yes                                              38                10.1                     23      6.4   
    N/A                                            202                 53.7                   184     50.8    
  Type of breast surgery                                                                                      
    Without surgery                                  37                  9.8                    24      6.6   0.078
    Lumpectomy                                       26                  6.9                    36      9.9   
    Quadrantectomy                                   87                23.1                     66    18.2    
    Mastectomy                                     224                 59.6                   234     65.6    
    N/A                                                2                 0.5                      2     0.6   
  Axillary surgery                                                                                            
    No                                               58                15.4                     62    17.1    0.219
    Yes                                            316                 84.0                   298     82.3    
    N/A                                                2                 0.5                      2     0.6   
  Number of lymph nodes dissected                                                                             
    1--10                                            61                16.2                     53    14.6    0.762
    11--15                                           76                20.2                     77    21.3    
    16--20                                           77                20.5                     86    23.8    
    ≥2                                             151                 40.2                   144     39.8    
    N/A                                              11                  2.9                      2     0.6   

TNM, tumor-node-metastasis staging. N/A, not available.

###### 

Treatment of patients with breast cancer, stratified by age group.

                             ≤40 years (n=376)   50--69 years (n=362)                   
  -------------------------- ------------------- ---------------------- ------- ------- ---------
  Breast reconstruction                                                                 
    Without                  295                 78.5                   346     95.6    \<0.001
    Immediate                  35                  9.3                      6     1.7   
    Late                       43                11.4                       8     2.2   
    N/A                          3                 0.8                      2     0.6   
  Neoadjuvant chemotherapy                                                              
    No                       312                 83.0                   286     79.0    0.254
    Yes                        62                16.5                     71    19.6    
    N/A                          2                 0.5                      5     1.4   
  Chemotherapy                                                                          
    No                         52                13.8                     70    19.3    0.053
    Yes (adjuvant)           201                 53.5                   196     54.1    
    Yes (palliative)         120                 31.9                     92    25.4    
    N/A                          3                 0.8                      4     1.1   
  Hormone therapy                                                                       
    No                       206                 54.8                   176     48.6    
    Yes (adjuvant)           104                 27.7                   131     36.2    0.056
    Yes (palliative)           59                15.7                     51    14.1    
    N/A                          7                 1.9                      4     1.1   
  Radiotherapy                                                                          
    No                         69                18.4                     72    19.9    0.592
    Yes                      302                 80.3                   284     78.5    
    N/A                          5                 1.3                      6     1.7   

N/A, not available.

###### 

DSS according to the demographics of patients with breast cancer, stratified by age group.

                        ≤40 years (n=376)   50--69 years (n=362)                          
  --------------------- ------------------- ---------------------- ------- ------- ------ -------
  Period of treatment                                                                     
    1985--1990            59                46.1                   0.656     65    33.3   0.002
    1991--1996          108                 46.4                             78    42.0   
    1997--2002          208                 40.7                           217     60.0   
    N/A                     1                                                  2          
  Schooling, years                                                                        
    0--8                210                 42.5                   0.751   279     50.0   0.551
    9--11               106                 48.5                             32    44.6   
    ≥12                   57                47.5                             34    38.5   
    N/A                     3                                                17           
  Overweight                                                                              
    No                  284                 48.1                   0.624   219     47.5   0.978
    Yes                   44                34.1                             90    44.9   
    N/A                   48                                                 53           
  Ethnicity                                                                               
    White               297                 46.0                   0.534   288     50.1   0.129
    Non-white             76                42.7                             70    41.0   
    N/A                     3                                                  4          
  Marital status                                                                          
    Married             254                 44.2                   0.538   214     52.2   0.170
    Single/divorced     110                 49.5                           134     42.6   
    N/A                   12                                                 14           

DSS, disease-specific survival; N/A, not available.

###### 

DSS according to the clinical characteristics of patients with breast cancer, stratified by age group.

                            ≤40 years (n=376)   50--69 years (n=362)                                  
  ------------------------- ------------------- ---------------------- ------- ------- ------ ------- --
  Palpable nodules                                                                                    
    No                        19                66.7                   0.216     20    78.9   0.062   
    Yes                     356                 43.9                           338     46.3           
    N/A                         1                                                  4                  
  Multicentric cancer                                                                                 
    No                      358                 46.8                   0.413   344     48.9   0.428   
    Yes                       11                26.0                               5   50.0           
    N/A                         7                                                12                   
  Multifocal cancer                                                                                   
    No                      346                   6.2                  0.799   341     48.4   0.634   
    Yes                       23                43.3                               9   66.7           
    N/A                         1                                                12                   
  Second cancer                                                                                       
    No                      371                 45.7                   0.004   352     47.8   0.545   
    Yes                         4               25.0                               7   71.4           
    N/A                         8                                                  3                  
  Bilateral breast cancer                                                                             
    No                      331                 48.5                   0.100   336     48.8   0.575   
    Yes                       37                30.1                             21    46.2           
    N/A                         8                                                  5                  
  Familial history                                                                                    
    No                      211                 38.8                   0.086   181     54.9   0.495   
    Yes                       49                56.7                             36    61.7           
    Other malignancies        74                46.6                             53    36.0           
    N/A                       42                                                 92                   
  Menopause at diagnosis                                                                              
    No                      363                 45.4                   0.026     38    28.5   0.283   
    Yes                         7               19.0                           226     45.4           
    N/A                         6                                                98                   
  Associated diseases                                                                                 
    Absent                  256                 40.2                   0.077   145     53.1   0.925   
    1 or 2 diseases         114                 55.7                           175     42.8           
    ≥3 diseases                 5               40.0                             40    46.3           
    N/A                         1                                                  2                  

DSS, disease-specific survival; N/A, not available.

###### 

OS according to the histological characteristics of patients with breast cancer, stratified by age group.

                                                   ≤40 years (n=376)   50--69 years (n=362)                            
  ------------------------------------------------ ------------------- ---------------------- --------- ------- ------ ---------
  Histological diagnosis                                                                                               
    Ductal carcinoma                               301                 47.8                   0.212     289     46.4   0.429
    Lobular carcinoma                                59                32.4                               54    58.2   
    Miscellaneous                                    15                53.0                               17    58.5   
    N/A                                                1                                                    2          
  Tumor size (mastectomy)                                                                                              
    ≤2 cm                                            54                65.0                   0.075       74    57.1   0.042
    \>2 cm                                         187                 49.9                             195     52.1   
    N/A                                            135                                                    93           
  Stage                                                                                                                
    I                                                38                90.9                   \<0.001     37    66.8   \<0.001
    II                                             136                 66.2                             135     67.6   
    III                                            101                 20.4                             122     28.3   
    IV                                               44                0.049                              39    --     
    N/A                                              57                                                   29           
  T^[a](#tfn7-ol-0-0-5360){ref-type="table-fn"}^                                                                       
    TI/TII                                         196                 56.8                   \<0.001   210     62.8   \<0.001
    TIII/TIV                                         84                32.6                             106     26.5   
    N/A                                              94                                                   46           
  N^[a](#tfn7-ol-0-0-5360){ref-type="table-fn"}^                                                                       
    Negative                                       147                 70.3                   \<0.001   156     70.1   \<0.001
    Positive                                       197                 32.3                             170     33.3   
    N/A                                              32                                                   36           
  M^[a](#tfn7-ol-0-0-5360){ref-type="table-fn"}^                                                                       
    No                                             311                 50.1                   \<0.001   311     50.4   \<0.001
    Yes                                              38                --                                 34    --     
    N/A                                              27                                                   17           
  Differentiation degree                                                                                               
    I/II                                           190                 45.1                   0.127     201     58.0   \<0.001
    III                                              87                46.9                               60    23.5   
    N/A                                              99                                                 101            
  Perineural invasion                                                                                                  
    No                                             241                 47.3                   0.056       84    65.0   0.095
    Yes                                              18                --                                 13    --     
    N/A                                            117                                                  278            
  Blood vessel invasion                                                                                                
    No                                             248                 45.9                   0.431       79    68.7   \<0.001
    Yes                                                4               --                                   7   --     
    N/A                                            124                                                  276            
  Lymphovascular invasion                                                                                              
    No                                             189                 53.8                   0.004       53    76.8   0.003
    Yes                                              80                30.5                               81    29.4   
    N/A                                            107                                                  228            
  Lymph node invasion                                                                                                  
    N1 (1 to 3)                                      78                53.7                   \<0.001     67    52.2   \<0.001
    N2 (4 to 9)                                      55                34.8                               49    13.8   
    N3 (≥10)                                         42                14.4                               35    --     
    N/A                                            201                                                  211            
  Estrogen receptor                                                                                                    
    Negative                                         89                16.7                   0.002       67    31.2   0.001
    Positive                                       126                 47.8                             155     60.4   
    N/A                                            161                                                  140            
  Progesterone receptor                                                                                                
    Negative                                         90                16.2                   0.043       85    46.3   0.015
    Positive                                       124                 49.0                             135     56.4   
    N/A                                            162                                                  142            
  C-erB-2 oncoprotein                                                                                                  
    Negative                                       117                 33.0                   0.332     125     66.5   0.006
    Positive                                         58                18.9                               53      50   
    N/A                                            201                                                  184            
  Triple negative                                                                                                      
    No                                             136                 25.2                   0.711     155       69   0.236
    Yes                                              38                26.0                               23    68.8   
    N/A                                            202                                                  184            
  Type of breast surgery                                                                                               
    Without surgery                                  37                --                     \<0.001     24    --     \<0.001
    Lumpectomy                                       26                    0                              36    35.3   
    Quadrantectomy                                   87                61.6                               66    75.7   \<0.001
    Mastectomy                                     224                 47.9                             234     46.6   
    N/A                                                2                                                    2          
  Axillary surgery                                                                                                     
    No                                               58                    0                  \<0.001     62    24.1   \<0.001
    Yes                                            316                 51.8                             298     52.3   
    N/A                                                2                                                    2          
  Number of lymph nodes dissected                                                                                      
    1 to 10                                          61                61.1                   \<0.001     53    53.3   0.005
    11 to 15                                         76                43.9                               77      42   
    16 to 20                                         77                63.8                               86    58.7   
    21 and over                                    151                 25.1                             144     40.9   
    N/A                                              11                                                     2          

TNM, tumor-node-metastasis staging. DSS, disease-specific survival; N/A, not available.

###### 

DSS according to the treatment of patients with breast cancer, stratified by age group.

                             ≤40 years (n=376)   50--69 years (n=362)                            
  -------------------------- ------------------- ---------------------- --------- ------- ------ ---------
  Breast reconstruction                                                                          
    Without                  295                 41.0                   \<0.001   346     47.7   0.263
    Immediate                  35                43.3                                 6   --     
    Late                       43                75.7                                 8   83.3   
    N/A                          3                                                    2          
  Neoadjuvant chemotherapy                                                                       
    No                       312                 48.4                   0.028     286     51.0   0.010
    Yes                        62                28.2                               71    37.3   
    N/A                          2                                                    5          
  Chemotherapy                                                                                   
    No                         52                65.5                   \<0.001     70    49.6   \<0.001
    Yes-adjuvant             201                 60.9                             196     62.5   
    Yes-palliative           120                 14.0                               92    19.0   
    N/A                          3                                                    4          
  Hormone therapy                                                                                
    No                       206                 51.8                   0.001     176     52.5   \<0.001
    Yes-adjuvant             104                 50.3                             131     53.2   
    Yes-palliative             59                10.8                               51    11.2   
    N/A                          7                                                    4          
  Radiotherapy                                                                                   
    No                         69                50.5                   0.935       72    36.7   0.016
    Yes                      302                 43.2                             284     52.9   
    N/A                          5                                                    6          

DSS, disease-specific survival; N/A, not available.

###### 

Multivariate survival analysis of patients aged ≤40 years (n=178).

  Variable                  n       Hazard ratio   95% confidence interval   P-value
  ------------------------- ------- -------------- ------------------------- ---------
  Bilateral breast cancer                                                    
    No                      158     --             --                        --
    Yes                       20    2.20           1.228--3.930              0.008
  Second cancer                                                              
    No                      176     --             --                        --
    Yes                         2   6.60           1.500--29.044             0.013
  Estrogen receptor                                                          
    Positive                106     --             --                        --
    Negative                  72    2.29           1.389--3.777              0.001
  T                                                                          
    I/II                    133     --             --                        --
    III/IV                    45    2.14           1.258--3.640              0.005
  N                                                                          
    No                        80    --             --                        --
    Yes                       98    2.66           1.531--4.621              0.001
  M                                                                          
    No                      173     --             --                        --
    Yes                         5   5.92           2.172--16.151             0.001

###### 

Multivariate survival analysis of patients aged 50--69 years (n=151).

  Variable                                         n       Hazard ratio   95% confidence interval   P-value
  ------------------------------------------------ ------- -------------- ------------------------- ---------
  Estrogen receptor                                                                                 
    Positive                                         44    --             --                        --
    Negative                                       107     2.34           1.175--4.663              0.016
  C-erB-2 oncoprotein                                                                               
    Negative                                       108     --             --                        --
    Positive                                         43    1.97           1.003--3.869              0.049
  T^[a](#tfn9-ol-0-0-5360){ref-type="table-fn"}^                                                    
    I/II                                           110     --             --                        --
    III/IV                                           41    2.12           1.073--4.180              0.030
  N^[a](#tfn9-ol-0-0-5360){ref-type="table-fn"}^                                                    
    No                                               71    --             --                        --
    Yes                                              80    2.93           1.394--6.149              0.005
  M^[a](#tfn9-ol-0-0-5360){ref-type="table-fn"}^                                                    
    No                                             150     --             --                        --
    Yes                                                1   9.99           1.049--95.105             0.045

TNM, tumor-node-metastasis staging.
